Modified tridegins, their preparation and their use as transglutaminase inhibitors
CA 2471373 A1 · Owner: Curacyte Ag · Inventors: Giersiefen, Helmut; Stoeckel, Johannes; Ohlmann, Marion
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to modified tridegins polypeptides derived from SEQ ID , No. 1 in which the modification is replacement of a cysteine residue and/or one of the following amino acids - Lys2 Lys7, His10, Gly12, Leu24, Tyr31, Phe34 Arg39, Ile45, Met48, Asp50, Pro55, Phe58 Asn60, Pro65, Arg66, by , another amino acid and/or N- or C-terminal deletion whereby the remaining , polypeptide comprises at least the amino acid sequence DDIYQRXVXFPXLPL (SEQ ID NO.89) and/or a covalent bonding to polyethylene glycol. Said polypeptides are novel inhibitors of transglutaminases, in particular of Factor XIIIa of the , terminal enzymes in the blood coagulation cascade. The invention further relates …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 20, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.